CDRI’s new research hub in Lucknow to facilitate innovation in drug discovery & development

Lucknow:  Marking 70 years of its inception, the Central Drug Research Institute (CDRI) in Lucknow launched a new and advanced research facility called Common Research and Technology Development Hub (CRTDH). As per the motive behind its establishment, this centre would be aiding hospitals and pharmaceutical sector entities in conducting clinical tests and trials. Besides, the latest hub would also facilitate MSMEs and academia with an avenue for high-level research.

The representative from CDRI was quoted saying “CRDTH is not only for scientists but for institutions conducting advanced research in the field of drug discovery. CDRI will not only provide infrastructure support like high-end laboratories and equipment but also the expertise of our scientists.”

With the cutting edge research and development projects undertaken by the CSIR-CDRI, the world has been gifted with a wide range of low-cost efficient drugs and medicines. Amongst its innovative contributions to the drug industry, the most prominent names are Centchroman, the first non-steroidal oral contraceptive and Arteether, a lifesaving drug for cerebral malaria.

In addition to being a top-notch organisation for the development and manufacturing of drugs, CDRI has worked on multiple initiatives to upgrade the quality of elementary research and strengthen human resources.

The CRTDH was inaugurated along with the launch of Atal National Colloquium on Healthcare and Innovation. As a part of this flagship program, a number of renowned and eminent personalities will hold sessions and lectures. This program has been planned to honour the erstwhile Prime Minister Atal Vihari Bajpayee’s vision, that considered scientific development, the topmost priority. This event was also marked by the announcement of the coveted CDRI Awards-2021 for Excellence in Drug Research.

Related Posts

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Food regulator FSSAI on Friday said it has suspended the licence of Punjab-based Rehaan Healthcare after it found serious violations of rules at the company’s health supplements and nutraceuticals manufacturing…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun

Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun